Ambulatory Use of Olanzapine and Risperidone: A Population-Based Study on Persistence and the Use of Concomitant Therapy in the Treatment of Schizophrenia
Open Access
- 1 December 2005
- journal article
- research article
- Published by SAGE Publications in The Canadian Journal of Psychiatry
- Vol. 50 (14) , 901-908
Abstract
Objective: To assess treatment discontinuation and concomitant use of other antipsychotics among individuals initiated on olanzapine or risperidone for the treatment of schizophrenia. Method: Using data from the Quebec health insurance plan and the Quebec database for hospitalization, we conducted a population-based cohort study of patients for whom a first claim for olanzapine or risperidone was submitted between 1 January 1997 and 31 August 1999. Included were 6405 patients with schizophrenia whom we followed from the date of the first claim for olanzapine or risperidone either to discontinuation date, end of eligibility for the drug plan, 365 days, date of moving out of the province, or date of death. We used Cox regression models to compute hazards ratios (HRs) of having the treatment discontinued and logistic regression models to compute odds ratios (ORs) among persisting patients of having any concomitant antipsychotic prescription. All models were adjusted for age, sex, schizophrenia disorder, comorbidity, region, beneficiary type, substance use disorder, and prior hospitalization for mental illness. Results: Compared with risperidone users ( n = 2718), discontinuation rates were lower for olanzapine users ( n = 3687; HR = 0.79; 95%CI, 0.74 to 0.84). The odds of receiving any concomitant antipsychotic prescription did not differ statistically between olanzapine and risperidone users (OR 0.85; 95%CI, 0.71 to 1.01). Conclusions: The study results suggest that new users of olanzapine were less likely to discontinue their initial treatment than were new users of risperidone, although discontinuation was high in both groups. Among those who persisted, concomitant use of other antipsychotics did not differ between olanzapine users and risperidone users.Keywords
This publication has 23 references indexed in Scilit:
- A Meta-analysis of the Efficacy of Second-Generation AntipsychoticsArchives of General Psychiatry, 2003
- Prescription of Antipsychotic Drugs by Office-Based Physicians in the United States, 1989-1997Psychiatric Services, 2002
- Clozapine, Olanzapine, Risperidone, and Haloperidol in the Treatment of Patients With Chronic Schizophrenia and Schizoaffective DisorderAmerican Journal of Psychiatry, 2002
- Clinical Outcome Following Neuroleptic Discontinuation in Patients With Remitted Recent-Onset SchizophreniaAmerican Journal of Psychiatry, 2001
- Atypical antipsychotics: are some more atypical than others?Psychopharmacology, 2000
- Antipsychotic Polypharmacy, Part 1: Therapeutic Option or Dirty Little Secret?The Journal of Clinical Psychiatry, 1999
- A Chronic Disease Score with Empirically Derived WeightsMedical Care, 1995
- The use of prescription claims databases in pharmacoepidemiological research: The accuracy and comprehensiveness of the prescription claims database in QuébecJournal of Clinical Epidemiology, 1995
- Cost of Relapse in SchizophreniaSchizophrenia Bulletin, 1995
- A chronic disease score from automated pharmacy dataJournal of Clinical Epidemiology, 1992